check_circleStudy Completed

Hormone replacement therapy (HRT)

Angeliq low/low: MD PK

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
24
Trial Dates
April 2009 - July 2009
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Low-Dose E2/DRSP (BAY86-4891)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Schering Pharma AGBerlin, 13353, Germany

Trial design

Open-label, randomized, mono-center study to investigate the pharmacokinetics of 17beta-estradiol (E2) and drospirenone (DRSP) after multiple oral administration of 2 tablet formulations containing 0.5 mg E2 in combination with either 0.5 or 0.25 mg DRSP in 24 healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A